United States Herceptin Market By Product (Biologic, Biosimilar), By Application (Breast Cancer, Stomach/Gastric Cancer, Others), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

United States Herceptin Market was valued at USD 1.32 Billion in 2024 and is expected to reach USD 1.74 Billion by 2030 with a CAGR of 4.66%. The United States Herceptin market is experiencing steady momentum due to increasing incidences of HER2-positive breast and gastric cancers, where trastuzumab remains a cornerstone therapy. Rising cancer awareness, coupled with enhanced screening programs and early diagnostic efforts, has led to a broader patient base eligible for Herceptin-based treatments. The continued adoption of monoclonal antibody therapies by oncologists, supported by clinical efficacy and long-term survival data, is reinforcing its use as a frontline and adjuvant treatment. Strong support from private and government insurance providers for biologics is helping reduce the financial burden for patients, facilitating broader uptake. The presence of a structured healthcare delivery system, high levels of oncological research, and strong patient access programs have further contributed to consistent prescription volumes across major health institutions.

A significant trend reshaping the Herceptin market is the rising penetration of trastuzumab biosimilars. Multiple biosimilar versions approved by the U.S. FDA have introduced competitive pricing, increasing affordability and accessibility of treatment. This biosimilar wave is encouraging wider adoption in smaller practices and rural care settings. Many providers are shifting toward combination therapies, integrating Herceptin with other HER2-targeted agents like pertuzumab or antibody-drug conjugates, based on updated NCCN guidelines and evolving clinical practice patterns. Healthcare providers are leveraging electronic health record systems and precision medicine tools to ensure patient-tailored treatment regimens, often involving Herceptin in various stages of cancer management. Pharmaceutical manufacturers are actively engaging in value-based contracts and collaborative programs with payers, enabling sustained drug access despite growing cost pressures.

Despite its established therapeutic value, the Herceptin market in the U.S. faces notable challenges. Patent expirations and the influx of biosimilars have significantly eroded the original brand's market share, forcing originator companies to revisit pricing and promotional strategies. Cost containment policies by insurers are placing pressure on reimbursement margins, especially when alternative HER2 therapies demonstrate comparable or superior outcomes in certain patient subgroups. Physician hesitancy regarding biosimilar switching, although declining, still exists in segments of the healthcare community, affecting rapid substitution rates. Inconsistent insurance coverage for combination regimens and high out-of-pocket costs for some patients create barriers to optimal therapy.

Key Market Drivers

Rising Prevalence of HER2-Positive Cancers

​The United States Herceptin market is witnessing steady expansion, supported by the increasing prevalence of HER2-positive cancers and the growing emphasis on precision oncology. HER2, or human epidermal growth factor receptor 2, plays a key role in tumor aggressiveness and recurrence, making its identification critical for effective treatment. According to the Surveillance, Epidemiology, and End Results (SEER) Program, HER2-positive subtypes, including HR+/HER2+ and HR-/HER2+, account for approximately 13.6% of all female breast cancer cases in the United States. This translates into a significant patient base requiring targeted therapies like Herceptin. Breast cancer remains the most diagnosed cancer globally, with 2.3 million new cases in 2022 per WHO data, further underlining the need for HER2-focused treatments. The adoption of routine HER2 testing and the integration of Herceptin into first-line and adjuvant therapy regimens are key drivers of its continued use.

The market is also being shaped by changes in therapeutic approaches and delivery mechanisms. Subcutaneous formulations of Herceptin have been gaining ground due to their ease of administration and reduced infusion time. New clinical guidelines promoting shorter duration regimens have increased treatment efficiency without compromising outcomes. Advances in diagnostics have resulted in earlier and more accurate detection of HER2 status, broadening the scope of eligible patients. In parallel, combination therapies involving trastuzumab with chemotherapy, pertuzumab, or immunotherapeutics are driving clinical innovation. Increased awareness and training among healthcare providers are ensuring more consistent testing practices, and patient adherence support programs are helping improve long-term outcomes. These evolving dynamics are reinforcing Herceptin’s place as a foundational therapy in HER2-positive cancer care.

Amid strong market fundamentals, notable growth opportunities exist. HER2-positive gastric and gastroesophageal junction (GEJ) cancers, though less common than breast cancer, are increasing in prevalence, with genetic and lifestyle influences contributing to higher incidence globally. Emerging research is exploring Herceptin’s role in other HER2-expressing malignancies such as lung, bladder, and colorectal cancers. The expanding utility of companion diagnostics and liquid biopsies will improve identification and monitoring of HER2-positive disease, enabling more targeted treatment delivery. Biosimilar versions of trastuzumab are making significant inroads in underinsured and cost-sensitive segments, ensuring broader patient access. As artificial intelligence and big data analytics are adopted across oncology workflows, treatment planning involving Herceptin will become even more personalized. These trends collectively point toward a future where Herceptin continues to be a high-value asset in oncology, supported by clinical necessity, technological progress, and expanding patient need.

Favorable Government Initiatives and Reimbursement Policies

Favorable government initiatives and reimbursement policies have become a primary driver of growth in the United States Herceptin market. The country’s healthcare framework supports broad access to oncology biologics like trastuzumab through robust public insurance programs. Medicare Part B covers trastuzumab for approved HER2-positive indications administered in outpatient settings, significantly reducing out-of-pocket costs for elderly and disabled patients. According to the Centers for Medicare & Medicaid Services (CMS) 2024 National Health Expenditure (NHE) report, Medicare spending on physician-administered drugs, including cancer therapies like Herceptin, reached approximately USD 29.2 billion in 2023, reflecting a steady annual increase. This spending trend indicates the federal government’s continued commitment to subsidizing high-cost treatments for critical conditions such as breast and gastric cancer.

The Affordable Care Act continues to mandate coverage of essential health benefits, which include oncology drugs, under qualified health plans, enabling increased access to trastuzumab through both Medicaid and commercial insurers. As of 2023, Medicaid enrollment reached over 85 million beneficiaries, according to the Medicaid and CHIP Payment and Access Commission (MACPAC), many of whom gain access to critical oncology care through expanded eligibility and state-administered drug assistance programs. Biosimilar inclusion in Medicare formularies, prompted by cost-efficiency measures from the U.S. Department of Health and Human Services (HHS), has driven competitive pricing for trastuzumab products, improving affordability without sacrificing therapeutic value.

Government-funded cancer initiatives such as the Cancer Moonshot program have further supported early detection, research, and access to targeted therapies like Herceptin. These national efforts, along with outcomes-based reimbursement agreements, encourage healthcare providers to adopt advanced biologic treatments while aligning with value-based care objectives. Through structured policy interventions, coverage mandates, and rising public health investment, the U.S. government plays a vital role in expanding access to trastuzumab and driving sustained market growth in the Herceptin landscape.

Development of New Formulations

The development of new formulations is significantly driving the growth of the United States Herceptin Market. Pharmaceutical innovations have led to the introduction of more patient-centric versions of trastuzumab, including subcutaneous (SC) formulations, which offer greater convenience, reduced administration time, and improved patient compliance compared to the traditional intravenous (IV) versions. These innovations have transformed the treatment landscape by minimizing the burden on healthcare facilities and reducing the time patients spend in clinical settings. For instance, subcutaneous trastuzumab can be administered in approximately 2–5 minutes compared to the 30–90 minutes required for IV infusion, allowing for more efficient use of healthcare resources.​

The development of fixed-dose combinations, such as trastuzumab with pertuzumab in a single subcutaneous injection, has also gained momentum. These combinations enhance therapeutic efficacy while improving the overall patient experience. In 2020, the U.S. Food and Drug Administration (FDA) approved Phesgo, a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous use, marking a significant advancement in breast cancer treatment. This approval was based on the pivotal phase III FeDeriCa study, which demonstrated that Phesgo produced non-inferior levels of pertuzumab and trastuzumab in the blood compared to IV administration, with comparable efficacy and safety profiles. These regulatory approvals have contributed to greater adoption across oncology practices and accelerated uptake in both developed and emerging markets.​

New formulations have also shown strong potential in addressing resistance to trastuzumab monotherapy. Research and development are ongoing to design next-generation antibody-drug conjugates and biosimilars with modified structures that offer enhanced stability, targeted delivery, and reduced side effects. These innovations expand therapeutic options and reinforce Herceptin’s position as a foundational therapy in HER2-positive cancer treatment. By improving delivery mechanisms, extending patient access, and enhancing therapeutic value, the evolution of trastuzumab formulations plays a pivotal role in shaping the future trajectory of the Herceptin market and driving sustained global demand.

Download Free Sample Report

Key Market Challenges

Patent Expiry and Growing Biosimilar Competition

One of the most pressing challenges facing the United States Herceptin market is the impact of patent expiry and the subsequent influx of biosimilar competition. Herceptin’s primary patents expired in the U.S. in 2019, opening the market to multiple biosimilar entrants approved by the FDA, including Kanjinti, Ogivri, Trazimera, Herzuma, and Ontruzant. These biosimilars are approved for the same indications as Herceptin, offering similar efficacy and safety profiles at significantly lower prices. The introduction of these alternatives has created substantial downward pricing pressure, forcing the originator manufacturer to implement discount strategies or risk rapid market share erosion.

As of 2023, biosimilars accounted for over 60% of trastuzumab prescriptions in several large oncology networks in the United States, indicating strong uptake driven by payers and healthcare institutions aiming to reduce treatment costs. Pharmacy benefit managers and hospital procurement departments are incentivizing the use of biosimilars through formulary positioning and rebate-driven agreements, further marginalizing the branded product. Physicians, while initially hesitant, are increasingly confident in prescribing biosimilars due to growing clinical familiarity and supportive real-world evidence. Despite robust brand loyalty and legacy clinical data, Herceptin’s market dominance is declining as stakeholders prioritize cost-efficiency. The challenge intensifies as biosimilar manufacturers expand production capacity and strengthen distribution networks, ensuring stable supply and competitive pricing.

As oncology care continues shifting toward value-based models, originator biologics like Herceptin must navigate tighter margins and heightened scrutiny around cost-effectiveness. The competition is not limited to price but also includes aggressive marketing efforts, provider education, and patient access programs designed by biosimilar manufacturers to gain loyalty and drive usage. Without significant differentiation or next-generation formulations, Herceptin’s long-term commercial sustainability in the U.S. is increasingly vulnerable in a maturing biosimilar environment shaped by cost-conscious policies and treatment standardization.

Adverse Effects and Resistance Concerns

One of the most pressing challenges in the United States Herceptin Market is the issue of adverse effects and the growing concerns regarding resistance among patients undergoing trastuzumab therapy. Herceptin, while being a cornerstone in the treatment of HER2-positive cancers, is associated with several side effects that can impact patient compliance and treatment outcomes. Common side effects include fever, chills, nausea, headaches, and fatigue, which are often manageable but can reduce the quality of life. More severe adverse reactions, such as cardiotoxicity, pose significant clinical concerns. Cardiac dysfunction, especially congestive heart failure, has been documented in a subset of patients receiving Herceptin, particularly when used in combination with anthracyclines. This necessitates continuous cardiac monitoring during treatment, increasing the burden on healthcare systems and patients alike.

Beyond adverse reactions, a critical issue that limits Herceptin’s long-term efficacy is the emergence of resistance. Both primary and acquired resistance mechanisms have been reported, where cancer cells adapt and become less responsive to trastuzumab therapy. Molecular alterations such as the activation of alternative signaling pathways, loss of HER2 expression, or mutations in the PI3K/Akt pathway contribute to this resistance. These biological adaptations diminish the effectiveness of the drug, leading to disease progression despite treatment. Resistance challenges complicate treatment planning, often requiring a shift to second-line or combination therapies, which may not be as well-tolerated or widely accessible. The development of novel HER2-targeted agents is underway, but their availability and integration into standard protocols remain limited in many regions. This ongoing issue not only hampers patient prognosis but also restricts the full therapeutic potential of Herceptin in oncology care. Addressing these challenges requires greater investment in predictive diagnostics, alternative therapeutic strategies, and supportive care mechanisms to enhance treatment tolerability and durability.

Key Market Trends

Shift Toward Combination and Sequential Therapies

​A growing trend shaping the United States Herceptin Market is the strategic shift toward combination and sequential therapies, aimed at enhancing the efficacy of HER2-targeted treatment while overcoming resistance in HER2-positive cancers. Herceptin (trastuzumab), once used primarily as monotherapy or alongside standard chemotherapy, is now widely incorporated in multi-drug regimens that include other monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates (ADCs). This trend is largely driven by increasing clinical evidence supporting superior patient outcomes when Herceptin is used in combination approaches. For instance, combining Herceptin with pertuzumab and docetaxel in metastatic breast cancer has been shown to significantly improve progression-free and overall survival, a finding that has been integrated into major oncology treatment guidelines.

Antibody-drug conjugates like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (Enhertu) have also entered the clinical landscape, leveraging Herceptin’s targeting ability while delivering potent cytotoxic payloads directly to HER2-expressing cells. Sequential therapy strategies, wherein patients receive Herceptin followed by ADCs or tyrosine kinase inhibitors (TKIs), are also becoming standard practice, especially in relapsed or refractory cases. These advancements have expanded Herceptin’s utility from initial-line treatment to a cornerstone role across the treatment continuum.

The National Cancer Institute (NCI) reported in 2023 that approximately 20% of breast cancers diagnosed in the United States are HER2-positive, underscoring the substantial patient population that could benefit from these evolving treatment paradigms. Additionally, data from the U.S. Centers for Disease Control and Prevention (CDC) highlights that breast cancer remains the most diagnosed cancer among women, accounting for over 290,000 new cases in 2023 alone. With HER2-positive subtypes making up a significant portion, the demand for therapies that improve treatment outcomes including Herceptin-based combinations is expected to remain high. This transition toward multi-agent regimens solidifies Herceptin’s continued relevance in precision oncology and fuels market expansion.

Increased Use of Real-World Evidence (RWE)

​A prominent trend shaping the United States Herceptin market is the increased reliance on Real-World Evidence (RWE) to guide clinical decision-making, regulatory approvals, and market access strategies. Healthcare providers, payers, and manufacturers are leveraging RWE to evaluate the effectiveness, safety, and economic impact of trastuzumab in routine clinical practice. This data, derived from sources such as electronic health records, cancer registries, insurance claims, and patient-reported outcomes, is offering valuable insights beyond controlled clinical trial settings. RWE is playing a crucial role in understanding treatment adherence, disease progression, and long-term survival rates among diverse patient populations, especially elderly individuals and those with comorbidities who are often underrepresented in trials. Pharmaceutical companies are using RWE to support the differentiation of Herceptin and its biosimilars in value-based contracting, where reimbursement is increasingly linked to patient outcomes. Payers are also integrating RWE into formulary decision-making, reimbursement negotiations, and risk-sharing agreements to ensure cost-effective care.

The U.S. Food and Drug Administration (FDA) has encouraged the use of RWE to complement clinical trial data, particularly for post-market surveillance and label expansions. Collaborative initiatives such as the CancerLinQ platform by the American Society of Clinical Oncology (ASCO) are accelerating the collection of structured oncology data to support evidence-based treatment pathways involving trastuzumab. RWE is also enabling physicians to identify optimal treatment sequences, recognize patterns of resistance, and personalize therapy based on real patient experiences. This growing emphasis on real-world data is transforming Herceptin’s market dynamics by aligning drug utilization with measurable outcomes, improving transparency in clinical performance, and supporting sustainable access models. As stakeholders continue to embrace data-driven oncology care, RWE is expected to influence prescribing patterns, boost stakeholder confidence, and reinforce Herceptin’s clinical relevance amid increasing competition and evolving cancer treatment standards.

Segmental Insights

Distribution Channel Insights

Based on the Distribution Channel, Hospital Pharmacy emerged as the dominant segment in the United States Herceptin Market in 2024. This dominance is due to the nature of trastuzumab administration, which typically requires intravenous or subcutaneous infusion under professional supervision. As a targeted biologic therapy primarily used in the treatment of HER2-positive breast and gastric cancers, Herceptin is most often administered in oncology centers and specialized hospital settings where proper monitoring and dosing precision can be ensured. Hospitals also have the infrastructure to manage potential adverse reactions, track patient progress, and comply with safety protocols, making them the preferred point of access for such therapies.

Download Free Sample Report

Regional Insights

The Mid-West region emerged as the dominant region in the United States Herceptin Market in 2024. This is driven by a combination of strong healthcare infrastructure, increasing cancer prevalence, and favorable reimbursement policies. The region hosts several leading oncology centers and research institutions that facilitate early diagnosis and advanced treatment of HER2-positive breast and gastric cancers, where Herceptin (trastuzumab) plays a critical role. States such as Illinois, Michigan, and Ohio have demonstrated a higher rate of patient access to biologic therapies due to well-established specialty pharmacy networks and hospital affiliations. Moreover, rising awareness campaigns by regional cancer societies and support organizations have contributed to improved screening rates, leading to greater adoption of targeted therapies like Herceptin. Collaborative clinical research between academic medical centers and pharmaceutical companies has further increased the availability and trust in monoclonal antibody treatments across the region.

Recent Developments

• In February 2025, results from the phase 2 ABCSG-52/ATHENE trial published in Nature Cancer confirmed that adding atezolizumab (Tecentriq) to trastuzumab (Herceptin) and pertuzumab, along with abbreviated epirubicin monotherapy, is effective and safe for treating early HER2-positive breast cancer. The treatment achieved a 60.3% pathologic complete response (pCR) rate in the intent-to-treat population. Patients receiving the atezolizumab-based combination had a higher pCR rate of 65.5%, compared to 55.2% in those treated with trastuzumab and pertuzumab alone.
• In January 2025, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adults with unresectable or metastatic, hormone receptor–positive, HER2-low or HER2-ultralow breast cancer that has progressed after at least one endocrine therapy. Approval was based on results from the phase 3 DESTINY-Breast06 trial, where Enhertu reduced the risk of disease progression or death by 36% compared to chemotherapy. Patients treated with Enhertu had a median progression-free survival of 13.2 months versus 8.1 months with chemotherapy, and a 62.6% overall response rate, significantly higher than the 34.4% seen with chemotherapy.
• In September 2024, the FDA approved trastuzumab-strf, a 420 mg trastuzumab biosimilar, for the treatment of HER2-positive cancers, including metastatic breast and gastric/gastroesophageal junction cancers. Accord BioPharma aims to improve access to affordable cancer therapies through biosimilars, addressing both clinical needs and cost challenges in oncology care
• In September 2024, Accord BioPharma, Inc., the U.S. specialty arm of Intas Pharmaceuticals, announced FDA approval of a 420mg dose of HERCESSI (trastuzumab-strf), a biosimilar to Herceptin, for treating HER2-positive breast and gastric cancers. This follows the earlier approval of a 150mg dose and positions the company to launch its first U.S. biosimilar in early 2025.
• In February 2024, Merck, known as MSD outside the U.S. and Canada, announced that Health Canada approved KEYTRUDA (pembrolizumab) in combination with trastuzumab and chemotherapy for first-line treatment of adults with HER2-positive, PD-L1-expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval is based on positive results from the Phase 3 KEYNOTE-811 trial, which showed significant improvement in progression-free survival.

Key Market Players

• Roche Holding AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Amgen Inc.
• Celltrion Healthcare Co., Ltd.
• Biocon Limited
• Mylan N.V. (Viatris)
• Prestige Biopharma
• Shanghai Henlius Biotech, Inc.
• Dr. Reddy’s Laboratories

Report Scope:

In this report, the United States Herceptin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Herceptin Market, By Product:

o   Biologic

o   Biosimilar

• United States Herceptin Market, By Application:

o   Breast Cancer

o   Stomach/Gastric Cancer

o   Others

• United States Herceptin Market, By Distribution Channel:

o   Hospital Pharmacy

o   Specialty Pharmacy

o   Others

• United States Herceptin Market, By Region:

o   North-East

o   Mid-West

o   West

o   South

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Herceptin Market.

Available Customizations:

United States Herceptin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United States Herceptin Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]